Sickle Cell Disease Clinical Trial
Official title:
Niacin Therapy to Improve Endothelial Function in Sickle Cell Disease
Verified date | December 24, 2015 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will determine whether niacin can improve blood flow in people with sickle cell
disease, in which abnormal red blood cells interfere with blood flow to cause the disease
symptoms. Niacin, a drug that has been used to increase HDL (good cholesterol) levels,
improves blood flow in people without sickle cell disease. This study will see if it can do
the same in people with the disease.
Patients with sickle cell disease between 18 and 65 years of age may be eligible for this
study.
Candidates are screened with a medical history, physical examination, blood tests,
echocardiogram and 6-minute walk test of exercise capacity.
Participants have the following baseline blood flow studies:
- Flow-mediated dilation (FMD): An ultrasound picture of the artery in the forearm is
obtained. A blood pressure cuff is then placed on the upper arm and inflated for 5
minutes. After the pressure cuff is released, the ultrasound is repeated.
- Peripheral artery tonometry (PAT): A sensor is placed on the subject s finger. The
sensor puts pressure on the finger and measures blood flow.
- Standard forearm blood flow test: Small tubes are placed in the artery of the forearm at
the inside of the elbow. Saline is infused into one tube. Pressure cuffs are applied to
the wrist and upper arm. A strain gauge (rubber band device) is placed around the
forearm. When the cuffs are inflated, blood flows into the arm, stretching the strain
gauge, and the flow measurement is recorded. Blood samples are collected from the tube
in the artery to measure blood counts, proteins and other chemicals. At various times,
small doses of the following drugs are administered through the tube in the vein:
- Sodium nitroprusside causes blood vessels to dilate and increases blood flow to the
heart.
- Acetylcholine causes blood vessels to dilate and slows heart rate.
- LNMMA decreases blood flow by blocking the production of nitric oxide.
Blood flow is measured after each dose of the different drugs. There are rest periods between
injections of the different drugs. Pictures of the forearm are taken during the studies using
an infrared camera and computer.
-Drug Treatment. Participants are assigned to take three 4-week courses of niacin or placebo.
They return to the Clinical Center at the following intervals from the time they start the
test drug for followup:
- Weeks 2, 6 and 10: Brief medical history, review of medication side effects and blood
tests.
- Weeks 4 and 8: Physical examination, brief medical history, review of medication side
effects and blood tests, repeat FMD and PAT blood flow studies and 6-minute walk test.
- Week 12: Same as weeks 4 and 8 plus standard blood flow studies and echocardiogram.
Status | Completed |
Enrollment | 30 |
Est. completion date | December 24, 2015 |
Est. primary completion date | December 31, 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
- INCLUSION CRITERIA: - Males or females 18 to 65 years of age. - Diagnosis of sickle cell disease (electrophoretic or HPLC documentation of hemoglobin S only phenotype is required). - Hemoglobin greater than 5.5 grams per deciliter - Absolute reticulocyte count greater than 95,000 microliters if hemoglobin is less than 9.0 grams per deciliter. - An apoA-1 level lower than 99 milligrams per deciliter (median value among sickle cell subjects), or HDL-C level below 39 milligrams per deciliter (median value amongst our sickle cell cohort). EXCLUSION CRITERIA: - Acute pain crisis requiring intravenous analgesics within the last week. - Current pregnancy or lactation. - Hemoglobin SC disease, or hemoglobin A greater than 20% - Conditions that may independently affect endothelial function: 1. Diabetes mellitus 2. Cigarette smoking within one month 3. Uncontrolled hypertension - Serum creatinine greater than 2.0 milligram per deciliter - Serum alanine aminotransferase (ALT) greater than 3 times the upper limit of normal. (AST elevation will not be used as an exclusion criterion, since this is elevated in normal sickle cell subjects due to red cell lysis, even without liver injury) - Uric acid level greater than 8 or history of gout - History of GI bleeding within the past 6 months - Active peptic ulcer disease - Hemoglobin less than or equal to 5.5 grams per deciliter; however, subjects may return for evaluation at a later date. - No aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) for 1 week prior to forearm blood flow assessment and no caffeine the day of each forearm blood flow study. Subjects on opiates or acetaminophen will not be excluded. - Subjects taking sildenafil, vardenafil, tadalafil, L-arginine, fibrates (e.g., clofibrate, gemfibrozil, or fenofribrate) or inhaled nitric oxide within the last week will be excluded from the study. - Subjects taking any statin drug (e.g., fluvastatin, lovastatin, pravastatin, simvastatin, rosuvastatin) within the last four weeks will be excluded from the study. - Subjects taking prostaglandins such as epoprostenol or treprostinil will be excluded from the study. - Subjects with significant cardiac disease and/or known peripheral Arterial disease. - Subjects with significant hypotension. - Women who do not use birth control while participating in this study. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
United States | Howard University Hospital | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004 Oct 15;95(8):764-72. Review. — View Citation
Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol. 1998 Nov 5;82(9A):13Q-21Q. Review. — View Citation
Viswambharan H, Ming XF, Zhu S, Hubsch A, Lerch P, Vergères G, Rusconi S, Yang Z. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res. 2004 Apr 16;94(7):918-25. Epub 2004 Feb 26. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Effect of niacin-ER on endothelial dysfunction in the sickle cell. | 12 weeks | ||
Secondary | Effect of niacin therapy on HDL and apo A-I levels in subjects with sickle cell disease. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02567695 -
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT02630394 -
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT02565082 -
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
|
N/A |